Sunday, January 31, 2021 1:25:36 AM
Will be much sooner than summer, I cant say with conviction but my estimate is EUA by mid March latest, hoping for end of February. The team we have is too solid. Dec 23 PR said on pace for enrolment goals which previously were described as end of dec for 210 group. IMHO next few weeks we will hear phase 3 news . It is double blind so if for some reason dsmb doesn’t unblind trial which I doubt, info may not be shared until after EUA filing and potential approval. Full study tbc by end of say April may. EUA is what we’re looking for, with the team MF has in his corner.. dec 23 or said plans for EUA filing post dsmb review sooo.. that’s what moves us before the full study is complete. Just my two cents.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
